Patients with cancer, autoimmune, and inflammatory diseases often face limited treatment options with significant side effects. Existing proteasome inhibitors can lack selectivity, leading to off-target effects and reduced therapeutic efficacy.

IpiNovyx Bio is developing a new class of highly selective and reversible immunoproteasome inhibitors designed to offer improved safety and efficacy profiles. Our proprietary technology platform enables the discovery and development of novel compounds that precisely target the immunoproteasome pathway. This targeted approach aims to mitigate the systemic toxicities associated with less selective proteasome inhibitors. By focusing on reversibility, our inhibitors are engineered for controlled engagement with their target, potentially leading to better patient tolerability and more predictable therapeutic outcomes. This strategy is intended to transform the treatment landscape for a range of debilitating diseases.

Proprietary platform for the discovery of novel, selective, and reversible immunoproteasome inhibitors.

Focus on developing small molecule therapeutics targeting the immunoproteasome.

Compounds designed for improved safety and efficacy compared to existing proteasome inhibitors.

Potential applications in oncology, autoimmune diseases, and inflammatory conditions.

Preclinical stage development with a lead program anticipated to enter clinical trials in 2026.

The primary target audience includes pharmaceutical companies seeking to license or partner on novel oncology and immunology assets, as well as academic institutions and research organizations focused on proteasome biology.